Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
47 pending office actions • 20 art units • 43 examiners • 0 of 47 (0%) have an AI response strategy ready • 15 patents granted in the last 365 days
Flagship Pioneering Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 2 distinct examiners across 2 distinct art units. This means each action is being reviewed by a different person in a different specialized group. The 2 distinct art units involved suggest that the company's biotechnology filings are spread across different specialized units at the USPTO. This distribution requires a strategy that can address the specific requirements of multiple examination divisions.
The busiest examiner, WHITEMAN, BRIAN A, has 1 pending action. This is consistent with the 2 distinct examiners handling the 2 total pending office actions. With 2 distinct examiners and 2 distinct art units, there is no overlap in the current pending workload. Practitioners must manage 2 separate examiner relationships across 2 different art units, as each Biotechnology & Pharmaceuticals matter is being evaluated independently by a unique examiner and unit. The lack of overlap means each case will likely proceed on its own unique timeline and technical merits.
Based on the USPTO statutory response window for each pending office action. 20 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 20 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 12 (26%) |
| §103 only | 8 (17%) |
| §112 only | 2 (4%) |
| Double-patenting + other | 7 (15%) |
| Multi-statute (no §101) | 18 (38%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEITH, NANCY J | 2 | 74.7% | +44.1% |
| GILL, RACHEL B | 2 | 65.6% | +28.3% |
| DAUNER, JOSEPH G | 2 | 56.9% | +35.2% |
| GIBBS, TERRA C | 2 | 63.7% | +10.3% |
| KEOGH, MATTHEW R | 1 | 78.3% | +14.5% |
| SKIBINSKY, ANNA | 1 | 39.0% | +29.1% |
| HAUK TEODORO, PRICILA NMN | 1 | 50.0% | +0.0% |
| PAULS, JOHN A | 1 | 49.1% | +27.4% |
| SHIAO, REI TSANG | 1 | 79.8% | -33.6% |
| LEWIS, PATRICK T | 1 | 74.0% | +14.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19288411 | MULTI-TIERED TESTING FOR TRACKING DISEASE HETEROGENEITY | SKIBINSKY, ANNA | 50d overdue |
| 18469344 | SERPINA-MODULATING COMPOSITIONS AND METHODS | PERSONS, JENNA L | 49d overdue |
| 17756211 | Protein Structure Prediction | AUGER, NOAH ANDREW | 36d overdue |
| 17920752 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | GIBBS, TERRA C | 29d overdue |
| 16970216 | COMPOSITIONS AND METHODS FOR MEMBRANE PROTEIN DELIVERY | RIGA, MICHAEL ANGELO | 28d overdue |
| 18945759 | SYSTEMS AND METHODS FOR PATIENT TARGETED THERAPY DEVELOPMENT | PAULS, JOHN A | 23d overdue |
| 17792639 | MOLECULE DESIGN | SANFORD, DIANA PATRICIA | 23d overdue |
| 17795915 | COMPOSITIONS FOR TRANSLATION AND METHODS OF USE THEREOF | PYLA, EVELYN Y | 16d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19272711 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | LEITH, NANCY J | 89d overdue |
| 19272775 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | LEITH, NANCY J | 86d overdue |
| 19288411 | MULTI-TIERED TESTING FOR TRACKING DISEASE HETEROGENEITY | SKIBINSKY, ANNA | 50d overdue |
| 17920752 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | GIBBS, TERRA C | 29d overdue |
| 18945759 | SYSTEMS AND METHODS FOR PATIENT TARGETED THERAPY DEVELOPMENT | PAULS, JOHN A | 23d overdue |
| 18444227 | COMPOSITIONS AND METHODS FOR MAKING AND USING AN IMMORTALIZED LIBRARY | DAUNER, JOSEPH G | 2d overdue |
| 18474060 | COMPOSITIONS AND METHODS FOR MAKING AND USING AN IMMORTALIZED LIBRARY | DAUNER, JOSEPH G | 70d |
| 17920769 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | GIBBS, TERRA C | 86d |
| Art Unit | Apps |
|---|---|
| 1635 | 7 |
| 1636 | 4 |
| 1682 | 3 |
| 1637 | 3 |
| 1687 | 3 |
| 1631 | 2 |
| 1671 | 2 |
| 1633 | 2 |
| 1634 | 2 |
| 1663 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19303663 | METHODS AND COMPOSITIONS FOR THE MODIFICATION OF PLANTS | KEOGH, MATTHEW R | 1663 | §103§112 | Non-Final OA | — | Pending | Aug 19, 2025 |
| 19288411 | MULTI-TIERED TESTING FOR TRACKING DISEASE HETEROGENEITY | SKIBINSKY, ANNA | 1635 | §101§103 | Non-Final OA | 50d overdue | Pending | Aug 01, 2025 |
| 19272711 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | LEITH, NANCY J | 1636 | §103Other | Final Rejection | 89d overdue | Pending | Jul 17, 2025 |
| 19272775 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | LEITH, NANCY J | 1636 | §103Other | Final Rejection | 86d overdue | Pending | Jul 17, 2025 |
| 18877551 | ADAS COMPRISING TYPE 1 PILI | HAUK TEODORO, PRICILA NMN | — | §103 | Non-Final OA | — | Pending | Dec 20, 2024 |
| 18945759 | SYSTEMS AND METHODS FOR PATIENT TARGETED THERAPY DEVELOPMENT | PAULS, JOHN A | 3683 | §101§103DP | Final Rejection | 23d overdue | Pending | Nov 13, 2024 |
| 18850640 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | SHIAO, REI TSANG | — | §103§112 | Non-Final OA | — | Pending | Sep 25, 2024 |
| 18718549 | METHODS FOR ENRICHMENT OF CIRCULAR RNA UNDER DENATURING CONDITIONS | LEWIS, PATRICK T | — | §102§112 | Non-Final OA | — | Pending | Jun 11, 2024 |
| 18712809 | IMMUNOGENIC COMPOSITIONS AND THEIR USES | GILL, RACHEL B | — | §101§102§103§112DP | Non-Final OA | — | Pending | May 23, 2024 |
| 18712359 | VARICELLA-ZOSTER VIRUS IMMUNOGEN COMPOSITIONS AND THEIR USES | GILL, RACHEL B | — | §101§102§103§112Other | Non-Final OA | — | Pending | May 22, 2024 |
| 18703246 | MODULATORS OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | FAUST, AMBER KATHLEEN | — | §102§112 | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18590275 | HBB-MODULATING COMPOSITIONS AND METHODS | MEYERING, SHABANA SHABBEER | 1635 | §103Other | Final Rejection | — | Pending | Feb 28, 2024 |
| 18444227 | COMPOSITIONS AND METHODS FOR MAKING AND USING AN IMMORTALIZED LIBRARY | DAUNER, JOSEPH G | 1682 | §103§112 | Final Rejection | 2d overdue | Pending | Feb 16, 2024 |
| 18569924 | MODIFICATION OF PLANT MESSENGER PACKS | KAMM, JUDITH MARIE | 1611 | §103§112Other | Non-Final OA | — | Pending | Dec 13, 2023 |
| 18561964 | METHODS OF ENRICHING FOR CIRCULAR POLYRIBONUCLEOTIDES | RAVINDRA, KRISHNA NUGGEHALLI | — | §103§112 | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18554139 | COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS TO ACCEPTOR CELLS | LEONARD, ARTHUR S | 1631 | §101§102§103DP | Non-Final OA | — | Pending | Oct 05, 2023 |
| 18474060 | COMPOSITIONS AND METHODS FOR MAKING AND USING AN IMMORTALIZED LIBRARY | DAUNER, JOSEPH G | 1682 | §103§112DPOther | Non-Final OA | 70d | Pending | Sep 25, 2023 |
| 18469344 | SERPINA-MODULATING COMPOSITIONS AND METHODS | PERSONS, JENNA L | 1637 | §103§112Other | Non-Final OA | 49d overdue | Pending | Sep 18, 2023 |
| 18464035 | MULTIPLE-TIERED SCREENING AND SECOND ANALYSIS | LIN, JERRY | 1671 | §101§103§112DP | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18038630 | ADIPOGENIC CELL COMPOSITIONS AND METHODS | KIM, TAEYOON | 1631 | §101§102§112 | Non-Final OA | 13d | Pending | May 24, 2023 |
| 18173049 | INTRA-INDIVIDUAL ANALYSIS FOR PRESENCE OF HEALTH CONDITIONS | TURPIN, ZACHARY MARK | 1682 | §101DP | Final Rejection | — | Pending | Feb 22, 2023 |
| 18010857 | METHODS AND COMPOSITIONS FOR MODULATING CELLS AND CELLULAR MEMBRANES | RAHMAN, MASUDUR | 1633 | §102§103 | Final Rejection | 36d | Pending | Dec 17, 2022 |
| 18011008 | ADAS COMPRISING BACTERIAL SECRETION SYSTEMS | ZEMAN, ROBERT A | 1645 | §102§112 | Final Rejection | — | Pending | Dec 16, 2022 |
| 18061632 | TEMPLATE GUIDE RNA MOLECULES | ZARA, JANE J | 1637 | §102§103§112 | Non-Final OA | — | Pending | Dec 05, 2022 |
| 17925966 | IMMUNOGENIC COMPOSITIONS AND USES THEREOF | HILL, MYRON G | 1671 | §103DP | Final Rejection | — | Pending | Nov 17, 2022 |
| 17925920 | CORONAVIRUS ANTIGEN COMPOSITIONS AND THEIR USES | BUCKMASTER, MARLENE VRENI | 1672 | §103§112 | Final Rejection | 10d overdue | Pending | Nov 17, 2022 |
| 17920752 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | GIBBS, TERRA C | 1635 | §102§103Other | Final Rejection | 29d overdue | Pending | Oct 21, 2022 |
| 17920769 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | GIBBS, TERRA C | 1635 | §103§112DP | Final Rejection | 86d | Pending | Oct 21, 2022 |
| 17759838 | Conformal Inference for Optimization | THOMPSON, MILANA KAYE | 1687 | §102§103§112 | Non-Final OA | — | Pending | Jul 29, 2022 |
| 17795943 | DELIVERY OF COMPOSITIONS COMPRISING CIRCULAR POLYRIBONUCLEOTIDES | WHITEMAN, BRIAN A | 1636 | §103Other | Final Rejection | 6d | Pending | Jul 28, 2022 |
| 17795915 | COMPOSITIONS FOR TRANSLATION AND METHODS OF USE THEREOF | PYLA, EVELYN Y | 1633 | §101§102§103 | Final Rejection | 16d overdue | Pending | Jul 28, 2022 |
| 17795939 | COMPOSITIONS COMPRISING LINEAR POLYRIBONUCLEOTIDES FOR PROTEIN MODULATION AND USES THEREOF | JONES-FOSTER, ERICA NICOLE | 1656 | §103§112 | Non-Final OA | — | Pending | Jul 28, 2022 |
| 17792639 | MOLECULE DESIGN | SANFORD, DIANA PATRICIA | 1687 | §101§103 | Final Rejection | 23d overdue | Pending | Jul 13, 2022 |
| 17756211 | Protein Structure Prediction | AUGER, NOAH ANDREW | 1687 | §101§103§112 | Non-Final OA | 36d overdue | Pending | May 19, 2022 |
| 17577942 | RECOMBINASE COMPOSITIONS AND METHODS OF USE | MCLEOD, AFRICA MHAIRIE | 1635 | §112 | Final Rejection | 21d | Pending | Jan 18, 2022 |
| 17433655 | POLYRIBONUCLEOTIDES AND COSMETIC USES THEREOF | LIPPOLIS, ALEXANDRA ROSE | 1637 | §103Other | Final Rejection | 31d overdue | Pending | Aug 25, 2021 |
| 18846524 | NOVEL ANELLOVIRIDAE FAMILY VECTOR COMPOSITIONS AND METHODS | CANDELARIA, JULIANA IRENE | — | §101§102§103§112 | Non-Final OA | — | Pending | Sep 12, 2024 |
| 18559921 | ANELLOVECTORS AND METHODS OF USE | MATALKAH, FATIMAH KHALAF | 1638 | §103DP | Non-Final OA | — | Pending | Nov 09, 2023 |
| 18257483 | COMPOSITIONS AND METHODS FOR MODULATING MYC EXPRESSION | COFFA, SERGIO | 1658 | §112DP | Final Rejection | — | Pending | Jun 14, 2023 |
| 18201882 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | LEE, WILLIAM Y | 1623 | §112 | Non-Final OA | — | Pending | May 25, 2023 |
| 17754050 | COMPOSITIONS AND METHODS FOR MODULATING GENOMIC COMPLEX INTEGRITY INDEX | TAKENAKA, RISA | 1632 | §103§112 | Non-Final OA | — | Pending | Mar 22, 2022 |
| 17413297 | ANELLOSOMES FOR DELIVERING PROTEIN REPLACEMENT THERAPEUTIC MODALITIES | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §103Other | Final Rejection | 45d overdue | Pending | Jun 11, 2021 |
| 17218025 | TARGETED LIPID PARTICLES AND COMPOSITIONS AND USES THEREOF | TIWARI, VYOMA SHUBHAM | 1634 | §103 | Non-Final OA | — | Pending | Mar 30, 2021 |
| 16970216 | COMPOSITIONS AND METHODS FOR MEMBRANE PROTEIN DELIVERY | RIGA, MICHAEL ANGELO | 1634 | §103§112 | Final Rejection | 28d overdue | Pending | Aug 14, 2020 |
| 18440188 | CLEAVABLE LINKER-CONTAINING IONIZABLE LIPIDS AND LIPID CARRIERS FOR THERAPEUTIC COMPOSITIONS | HOLLOMAN, NANNETTE | 1612 | §102§103 | Non-Final OA | — | Pending | Feb 13, 2024 |
| 18283242 | PRODUCTION OF CIRCULAR POLYRIBONUCLEOTIDES IN A EUKARYOTIC SYSTEM | SULLIVAN, STEPHANIE LAUREN | 1635 | §103DP | Non-Final OA | — | Pending | Sep 21, 2023 |
| 18283262 | PRODUCTION OF CIRCULAR POLYRIBONUCLEOTIDES IN A PROKARYOTIC SYSTEM | BRETZ, COREY LANE | 1635 | §103DP | Non-Final OA | — | Pending | Sep 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial